GCC In-Vitro Diagnostics Market Size (2024 - 2029)

The GCC In-Vitro Diagnostics Market is projected to experience growth over the forecast period, driven by factors such as the increasing prevalence of chronic and infectious diseases, heightened healthcare expenditure, and the sustained demand for diagnostics following the COVID-19 pandemic. The market's expansion is further supported by the development and introduction of innovative diagnostic products by key market players. However, the growth trajectory may face challenges due to stringent regulatory requirements.

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research In Vitro Diagnostic Devices Research GCC In Vitro Diagnostics Industry Market Size

Market Size of GCC In-Vitro Diagnostics Industry

GCC In-Vitro Diagnostics Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 2.07 Billion
Market Size (2029) USD 2.66 Billion
CAGR (2024 - 2029) 5.10 %

Major Players

GCC In-Vitro Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

GCC In-Vitro Diagnostics Market Analysis

The GCC In-Vitro Diagnostics Market size is estimated at USD 2.07 billion in 2024, and is expected to reach USD 2.66 billion by 2029, growing at a CAGR of 5.10% during the forecast period (2024-2029).

COVID-19 significantly impacted the market's growth during the pandemic period owing to the notable impact on the demand for the Vitro diagnostics market. For instance, a research article published in NCBI Journal in December 2021 stated that the most prevalent comorbidity among COVID-19-positive patients was Diabetes Mellitus (DM) with a prevalence of 68.3%, hypertension with 42.6%, and obesity at 42.2%. Thus, the prevalence of DM was high among hospitalized Covid-19 patients at King Khaled University Hospital (KKUH), Riyadh, Saudi Arabia. Such high prevalence of diabetes mellitus and COVID-19 patients boosted the in-vitro diagnostics market during the pandemic period. In addition, the demand for in vitro diagnostics is expected to remain intact due to the emergence of mutant strains of the SARS-CoV-2 virus during the post-pandemic period, thereby contributing to the market's growth during the forecast period.

The growing burden of chronic diseases, infectious diseases, and increasing healthcare expenditure is expected to be the major driving factors for the growth of the market in GCC.

For instance, in the article published by Khaleej Times in November 2022, every year in the UAE, around 8,000 and 10,000 patients suffer from a stroke, equating to about one patient every hour. Such a surge in the prevalence of chronic heart diseases among the GCC population is expected to demand in-vitro diagnostics owing to early and effective diagnostics, thereby contributing to the market's growth. Additionally, the data published by the Ministry of Health in June 2022 mentioned that 90% of men were infected by HIV in Saudi Arabia annually, and 9 out of every 10 cases in Saudi Arabia remain undiagnosed due to a lack of advanced diagnostics. Such a diagnosed population in GCC is expected to drive the demand for in-vitro diagnostics for early and effective diagnosis, thereby contributing to the market's growth. Similarly, the Arab Times article published in July 2022 mentioned that in Kuwait, 26 people were infected with hepatitis B, 7 with hepatitis C, 57 with syphilis, and 3 with HIV from January 2022 to April 2022. Such incidence of chronic and infectious diseases among the GCC population leading to the demand for diagnostics is expected to drive the growth of the market during the forecast period.

The increasing market player's strategies to develop and launch innovative products in GCC are also expected to drive market growth. For instance, in February 2021, Lapiac Technology partnered with UAE-based Companies YAS pharmaceuticals and Pure Health to launch an Artificial Intelligence (AI)-based COVID-19 antigen test system.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, stringent regulations are likely to impede market growth.

GCC In-Vitro Diagnostics Industry Segmentation

As per the scope of the report, In-vitro diagnostics is defined as a medical device used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring, or compatibility purposes. 

The Gulf Cooperation Council In-vitro Diagnostics Market is segmented by Technique (Histochemistry, Molecular Diagnostics, Hematology, Self-blood Glucose Testing, Immunochemistry, and Other Techniques), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Device and Reusable IVD Device), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, and Other Applications), End User (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users), Diagnostic Approach (Point-of-Care Diagnostics, Centralized Laboratory-based, and Diagnostics). The report offers the value (in USD million) for the above segments.

By Technique
Histochemistry
Molecular Diagnostics
Hematology
Self-blood Glucose Testing
Immunochemistry
Other Techniques
By Product
Instrument
Reagent
Other Products
By Usability
Disposable IVD Device
Reusable IVD Device
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users
By Diagnostic Approach
Point-of-Care Diagnostics
Centralized Laboratory-based Diagnostics
Need A Different Region Or Segment?
Customize Now

GCC In-Vitro Diagnostics Market Size Summary

The GCC In-Vitro Diagnostics Market is poised for significant growth over the forecast period, driven by the increasing prevalence of chronic and infectious diseases, alongside rising healthcare expenditures. The market's expansion is further supported by the ongoing demand for advanced diagnostic solutions, a trend that was notably accelerated during the COVID-19 pandemic. The pandemic highlighted the critical role of in-vitro diagnostics, particularly in managing comorbidities such as diabetes, hypertension, and obesity, which were prevalent among COVID-19 patients. This heightened awareness and demand are expected to persist, especially with the emergence of new SARS-CoV-2 variants. The market is also witnessing a surge in innovative product developments and strategic partnerships, such as the collaboration between Lapiac Technology and UAE-based companies to launch AI-based diagnostic systems, which are anticipated to bolster market growth.

Saudi Arabia is expected to capture a significant share of the market, supported by favorable government policies and initiatives aimed at enhancing diagnostic capabilities. The country's focus on addressing the high incidence of chronic and infectious diseases, such as diabetes and hepatitis, is driving the demand for in-vitro diagnostics. Additionally, the launch of platforms like the Middle East oncology e-platform underscores the commitment to early disease detection and management. The point-of-care diagnostics segment is also projected to grow, driven by the need for rapid and accurate diagnostics in managing prevalent health conditions. The competitive landscape of the GCC In-Vitro Diagnostics Market is moderately fragmented, with key players like Abbott Laboratories, Danaher Corporation, and F. Hoffmann-La Roche AG playing pivotal roles in shaping the market dynamics.

Explore More

GCC In-Vitro Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Chronic Diseases and Infectious Diseases

      2. 1.2.2 Increasing Healthcare Expenditure

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulations

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Technique

      1. 2.1.1 Histochemistry

      2. 2.1.2 Molecular Diagnostics

      3. 2.1.3 Hematology

      4. 2.1.4 Self-blood Glucose Testing

      5. 2.1.5 Immunochemistry

      6. 2.1.6 Other Techniques

    2. 2.2 By Product

      1. 2.2.1 Instrument

      2. 2.2.2 Reagent

      3. 2.2.3 Other Products

    3. 2.3 By Usability

      1. 2.3.1 Disposable IVD Device

      2. 2.3.2 Reusable IVD Device

    4. 2.4 By Application

      1. 2.4.1 Infectious Disease

      2. 2.4.2 Diabetes

      3. 2.4.3 Cancer/Oncology

      4. 2.4.4 Cardiology

      5. 2.4.5 Autoimmune Disease

      6. 2.4.6 Other Applications

    5. 2.5 By End User

      1. 2.5.1 Diagnostic Laboratories

      2. 2.5.2 Hospitals and Clinics

      3. 2.5.3 Other End Users

    6. 2.6 By Diagnostic Approach

      1. 2.6.1 Point-of-Care Diagnostics

      2. 2.6.2 Centralized Laboratory-based Diagnostics

GCC In-Vitro Diagnostics Market Size FAQs

The GCC In-Vitro Diagnostics Market size is expected to reach USD 2.07 billion in 2024 and grow at a CAGR of 5.10% to reach USD 2.66 billion by 2029.

In 2024, the GCC In-Vitro Diagnostics Market size is expected to reach USD 2.07 billion.

GCC In Vitro Diagnostics Market Report Snapshots

GCC In Vitro Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)